FDA Clears Meridian's MDx Test for Group B Strep | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today announced the US Food and Drug Administration has cleared its molecular diagnostic test for Group B Streptocococcus (GBS).

The clearance is the second for a Meridian MDx test that runs on its illumigene platform, following FDA clearance of the Cincinnati-based firm's test for C.difficile in June 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.